Preventive Effect of a Novel Recombinant sTNFRII on Collagen-Induced Arthritis

References

• Chen S, He Q, Dong X, et al. (2010). Eukaryotic expression and bioactivity determination of the fusion protein sTNFRII-gAD consisting of soluble tumor necrosis factor receptor II and globular domain of adiponectin. Sheng Wu Gong Cheng Xue Bao, 26, 207–15
   PubMedGoogle Scholar
• Cooper WO, Fava RA, Gates CA, et al. (1992). Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol, 89, 244–50
   PubMed Web of Science ®Google Scholar
• Di Giovine FS, Nuki G, Duff GW. (1988). Tumour necrosis factor in synovial exudates. Ann Rheum Dis, 47, 768–72
   PubMed Web of Science ®Google Scholar
• Ehling A, Schaffler A, Herfarth H, et al. (2006). The potential of adiponectin in driving arthritis. J Immunol, 176, 4468–78
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, et al. (2004). Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med, 200, 277–85
   PubMed Web of Science ®Google Scholar
• Elliot M J, Maini RN, Feldmann M, et al. (2008). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum, 58, S92–S101
   PubMedGoogle Scholar
• Feldmann M, Maini RN. (2001). Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol, 19, 163–96
   PubMed Web of Science ®Google Scholar
• Firestein GS, Alvaro-Gracia JM, Maki R. (1990). Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol, 144, 3347–53
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. (2008). Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA, 105, 19396–401
   PubMed Web of Science ®Google Scholar
• Hopkins S J, Humphreys M, Jayson MI. (1988). Cytokines in synovial fluid: I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol, 72, 422–7
   PubMedGoogle Scholar
• Jones EY, Stuart DI, Walker NP. (1989). Structure of tumour necrosis factor. Nature, 338, 225–8
   PubMed Web of Science ®Google Scholar
• Kusunoki N, Kitahara K, Kojima F, et al. (2010). Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum, 62, 1641–9
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, Oppers-Walgreen B, et al. (2004). Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum, 50, 650–9
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, van den Berg WB. (2005). The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther, 7, 29–37
   PubMed Web of Science ®Google Scholar
• Luo M, Liu D, Zhang L, et al. (2012). Protective effects of a novel trimerized sTNFRII on acute liver injury. Int Immunopharmacol, 13, 88–92
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol, 7, 429–42
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DS, Smith CA, et al. (1993). Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 151, 1548–61
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sudo K, Iwakura Y. (2003). Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol, 171, 6173–7
   PubMed Web of Science ®Google Scholar
• Ranges GE, Sriram S, Cooper SM. (1985). Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med, 162, 1105–10
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155, 1151–64
   PubMed Web of Science ®Google Scholar
• Scherer PE, Williams S, Fogliano M, et al. (1995). A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 270, 26746–9
   PubMed Web of Science ®Google Scholar
• Shapiro L, Scherer PE. (1998). The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol, 8, 335–8
   PubMed Web of Science ®Google Scholar
• Smith RA, Baglioni C. (1987). The active form of tumor necrosis factor is a trimer. J Biol Chem, 262, 6951–4
   PubMed Web of Science ®Google Scholar
• Souza PP, Lerner UH. (2013). The role of cytokines in inflammatory bone loss. Immunol Invest, 42, 555–622
   PubMed Web of Science ®Google Scholar
• Tissi L, Puliti M, Bistoni F, et al. (2004). Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis. Infect Immun, 72, 6367–72
   PubMedGoogle Scholar
• Valencia X, Stephens G, Goldbach-Mansky R, et al. (2006). TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood, 108, 253–61
   PubMed Web of Science ®Google Scholar
• van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. (2004). CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum, 50, 2775–85
   PubMed Web of Science ®Google Scholar
• van den Berg WB. (2009). Lessons from animal models of arthritis over the past decade. Arthritis Res Ther, 11, 250
   PubMedGoogle Scholar
• Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, et al. (2005). Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol, 141, 372–80
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. (2008). How regulatory T cells work. Nat Rev Immunol, 8, 523–32
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum, 48, 35–45
   PubMed Web of Science ®Google Scholar
• Wherry JC, Pennington JE, Wenzel RP. (1993). Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med, 21, S436–40
   PubMedGoogle Scholar
• Williams RO, Ghrayeb J, Feldmann M, Maini RN. (1995). Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology, 84, 433–9
   PubMed Web of Science ®Google Scholar
• Wooley PH. (1988). Collagen-induced arthritis in the mouse. Methods Enzymol, 162, 361–73
   PubMed Web of Science ®Google Scholar
• Wooley PH, Dutcher J, Widmer MB, Gillis S. (1993). Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol, 151, 6602–7
   PubMed Web of Science ®Google Scholar
• Yang T, Wang Z, Wu F, et al. (2010). A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis. PLoS Comput Biol, 6, e1000669
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hashizume M, Mihara M. (2010). IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int, 31,127–31
   PubMedGoogle Scholar